First CAR T-Cell Therapies OK'd In EU: Novartis's Kymriah And Kite's Yescarta

 
• By Ian Schofield and Neena Brizmohun
Recommended
The CHMP has recommended nine products for marketing authorization in the EU

More from Approvals

More from Product Reviews